- Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This study looks at a new, higher dose of ocrelizumab for people with primary progressive multiple sclerosis (PPMS). Researchers want to see if this dose is safe and works better than the current approved dose to slow down the disease.
For: Multiple SclerosisUnited States · Argentina · Belgium - RecruitingPHASE3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
This study looks at a new medicine called remibrutinib for people with relapsing multiple sclerosis (RMS). It compares switching from their current medicine, ocrelizumab, to remibrutinib, versus staying on ocrelizumab, to see if it's safe and works well.
For: Relapsing Multiple SclerosisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study is looking at a new treatment called Ocrelizumab for primary progressive multiple sclerosis (PPMS). It compares Ocrelizumab to a dummy drug (placebo) to see how safe and effective it is for adults, including those who have had PPMS for a while.
For: Multiple Sclerosis, Primary ProgressiveUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study looks at a new medicine called ocrelizumab for children and teenagers aged 10-17 with a type of MS called relapsing-remitting multiple sclerosis (RRMS). It compares ocrelizumab to an existing medicine, fingolimod, to see how safe and effective it is over a period of time.
For: Relapsing-Remitting Multiple SclerosisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
This study is comparing two medicines, fenebrutinib and ocrelizumab, to see which is safer and better at slowing down primary progressive multiple sclerosis (PPMS). It's for adults with PPMS and aims to understand how these treatments affect the disease progression.
For: Multiple Sclerosis, Primary ProgressiveUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
This study looks at a new medicine called RO7268489 for people with progressive multiple sclerosis (MS) who are already taking ocrelizumab. We want to see if adding RO7268489 helps, and if it's safe. Some people might also get the new medicine after the main part of the study.
For: Progressive Multiple SclerosisAustralia · France · Germany - Active not recruitingPHASE3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This study looks at the long-term safety and effectiveness of a medicine called ocrelizumab for people with Multiple Sclerosis (MS). It's for people already taking part in other ocrelizumab studies, to see how the treatment works over a longer time.
For: Multiple SclerosisUnited States · Argentina · Australia - AuthorisedTherapeutic confirmatory (Phase III)
DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
This study compares different treatments for multiple sclerosis (MS) to see if a less intense approach is just as good as current treatments. It looks at how well people's MS is controlled over three years and checks for new symptoms or changes in brain scans.
For: Multiple sclerosisFrance - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
This study is testing a higher dose of a medicine called ocrelizumab for adults with a type of multiple sclerosis (MS) called relapsing MS. It compares the new dose to the standard dose to see if it's more effective and safe.
For: Multiple SclerosisUnited States · Argentina · Australia